The next generation of non-invasive prenatal screening.

Using a simple blood draw from the mother, Panorama™ provides sensitivity >99% and positive predicted value (PPV) > 91% for Down syndrome.  A microdeletion panel (including 22q11.2 deletion syndrome) is also available to provide unparalleled scope and reliability among non-invasive prenatal screens.


Expecting Parents
Learn More

Healthcare Providers
Learn More


Not all prenatal screens are created equal.  Click here to compare Panorama™ to other testing options. 



Click here to register for our webinar: "Early Detection Means Early Treatment for Children with Developmental Delays due to X and Y Chromosome Aneuploidies" by Carol Samango-Sprouse,Ed.D. This live webinar will be held on Wednesday, November 5 at 1 PM EST.